Journal of Clinical Oncology · 2018 · 47 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeuro-oncologyBrain TumorsCentral Nervous System Tumor PharmacotherapyGlioblastomaGlioma RadiotherapyRecurrent Brain TumorsToxicity ManagementCell Signaling PathwaysGlioblastoma Cell SignalingGlioblastoma Clinical TrialsGlioblastoma Drug TherapyGlioblastoma TrialsRadiotherapy Dose EscalationTemozolomide TherapyVoltage-gated Calcium Channels
Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non–voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models. We conducted a phase IB study combining CTO with two standard TMZ schedules in GBM. Methods In cohort 1, patients with recurrent anaplastic gliomas or GBM received escalating doses of CTO (219 to 812.5 mg/m 2 once daily or 600 mg fixed once-daily dose) combined with TMZ (150 mg/m 2 5 days during each 28-day cycle). In cohort 2, patients with newly diagnosed GBM received escalating doses of CTO (219 to 481 mg/m 2 /d once daily) with radiotherapy and TMZ 75 mg/m 2 /d, followed by TMZ 150 mg to 200 mg/m 2 5 days during each 28-day cycle. Results Forty-seven patients were enrolled. Treatment was well tolerated; toxicities included fatigue, constipation, nausea, and hypophosphatemia. Pharmacokinetics showed that CTO did not alter TMZ levels; therapeutic concentrations were achieved in tumor and brain. No dose-limiting toxicities were observed; the recommended phase II dose was 600 mg/d flat dose. Signals of activity in cohort 1 (n = 27) included partial (n = 6) and complete (n = 1) response, including in O 6 -methylguanine–DNA methyltransferase unmethylated and bevacizumab-refractory tumors. In cohort 2 (n = 15), median progression-free survival was 15 months and median overall survival was not reached (median follow-up, 28 months; 2-year overall survival, 62%). Gene sequencing disclosed a high rate of responses among EGFR-amplified tumors ( P = .005), with mechanisms of acquired resistance possibly involving mutations in mismatch-repair genes and/or downstream components TSC2, NF1, NF2, PTEN, and PIK3CA. Conclusion CTO can be combined safely with TMZ or chemoradiation in GBM and anaplastic gliomas, displaying favorable brain penetration and promising signals of activity in this difficult-to-treat population.
30
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · New England Journal of Medicine · 2014 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah Phillips et al. · JCO Precision Oncology · 2017 · 2.7K citations
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot, Wolfgang Wick, Warren Mason et al. · New England Journal of Medicine · 2014 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +15